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Background: Neurofibromatosis type-1 (NF1) is caused by mutations of the NF1 gene at 17q11.2. In 95% of
non-founder NF1 patients, NF1 mutations are identifiable by means of a comprehensive mutation analysis. 5-10% of
these patients harbour microdeletions encompassing the NF1 gene and its flanking regions. NF1 is characterised by
tumours of the peripheral nerve sheaths, the pathognomonic neurofibromas. Considerable inter- and intra-familial
variation in expressivity of the disease has been observed which is influenced by genetic modifiers unrelated to the
constitutional NF1 mutation. The number of plexiform neurofibromas (PNF) in NF1 patients is a highly heritable
genetic trait. Recently, SNP rs2151280 located within the non-coding RNA gene ANRIL at 9p21.3, was identified as
being strongly associated with PNF number in a family-based association study. The T-allele of rs2151280, which
correlates with reduced ANRIL expression, appears to be associated with higher PNF number. ANRIL directly binds to
the SUZ12 protein, an essential component of polycomb repressive complex 2, and is required for SUZ12
occupancy of the CDKN2A/CDKN2B tumour suppressor genes as well as for their epigenetic silencing.
Methods: Here, we explored a potential association of PNF number and PNF volume with SNP rs2151280 in 29
patients with constitutional NF1 microdeletions using the exact Cochran-Armitage test for trends and the exact
Mann–Whitney–Wilcoxon test. Both the PNF number and total tumour volume in these 29 NF1 patients were
assessed by whole-body MRI. The NF1 microdeletions observed in these 29 patients encompassed the NF1 gene as
well as its flanking regions, including the SUZ12 gene.
Results: In the 29 microdeletion patients investigated, neither the PNF number nor PNF volume was found to be
associated with the T-allele of rs2151280.
Conclusion: Our findings imply that, at least in patients with NF1 microdeletions, PNF susceptibility is not
associated with rs2151280. Although somatic inactivation of the NF1 wild-type allele is considered to be the
PNF-initiating event in NF1 patients with intragenic mutations and patients with NF1 microdeletions, both patient
groups may differ with regard to tumour progression because of the heterozygous constitutional deletion of SUZ12
present only in patients with NF1 microdeletions.* Correspondence: hildegard.kehrer-sawatzki@uni-ulm.de
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Neurofibromatosis type 1 (NF1; MIM# 613113) is an
autosomal dominant inherited disease, with an incidence
of 1 in 3000, caused by mutations of the NF1 gene at
17q11.2. In 95% of non-founder NF1 patients, NF1 gene
mutations are identified when a comprehensive NF1
mutation analysis is applied, including an RNA-based
core assay supplemented with methods to identify NF1
microdeletions [1]. The proportion of patients with large
deletions (termed NF1 microdeletions) that encompass
the entire NF1 gene and its flanking regions among all
patients with NF1 is 5–10 % [2].
NF1 is a tumour predisposition syndrome characterised
by tumours of the peripheral nerve sheaths including the
pathognomonic neurofibromas. Cutaneous or dermal
neurofibromas (DNF) usually grow during puberty or
early adulthood at the end of single peripheral nerves and
form small round tumours on the skin which never be-
come malignant. In contrast to DNF, plexiform neuro-
fibromas (PNF) grow along large nerve trunks involving
several nerve bundles and mostly represent much larger
and more complex tumours than DNF. PNF are usually
congenital [3], can grow continuously and may cause
organ compression, neurologic impairment and motor
dysfunction. At least 10% of all PNF transform into malig-
nant peripheral nerve sheath tumours (MPNST) which
are the major cause of NF1-associated mortality [4].
NF1 is associated with considerable inter- and intra-
familial variability in phenotypic expression. Nevertheless,
the familial aggregation of specific symptoms suggests the
influence of a strong genetic component unrelated to thetel
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within ANRIL intron 3.constitutional NF1 mutation [5,6]. One of the phenotypic
traits with the highest estimated heritability in NF1 is the
number of PNF, suggesting that one or more modifier
genes might influence PNF susceptibility [6]. Recently, a
single nucleotide polymorphism (SNP) rs2151280, located
within the non-coding RNA gene ANRIL at 9p21.3, has
been identified as being associated with the number of
PNF in a family-based association study [7]. ANRIL (anti-
sense non-coding RNA in the INK4 locus) is transcribed
in the antisense orientation to the CDKN2A/ARF and
CDKN2B genes (Figure 1) and is known to influence their
expression [8-10]. CDKN2A/ARF and CDKN2B are three
tumour suppressor genes which play a central role in cell
cycle inhibition, senescence and stress-induced apoptosis
[11]. Importantly, homozygous deletion or expression si-
lencing of these genes has been observed in a subset of
PNF, atypical neurofibromas (considered as premalignant
tumours) and MPNSTs indicative of their role during the
malignant progression of peripheral nerve sheath tumours
[7,12,13]. However, not only the malignant progression of
PNF but also their formation may be influenced by genes
at 9p21.3. This conclusion has been drawn from the
observed association between the number of PNF in NF1
families and SNP rs2151280 located within the ANRIL
gene. The T-allele of rs2151280 has been found to be asso-
ciated with a higher number of PNF [7]. These authors
investigated a total of 1105 individuals (740 NF1 patients
and 365 unaffected relatives from 306 French NF1 fam-
ilies). It is however unclear how the number of PNF was
assessed in these 740 NF1 patients. Whilst PNF can be ex-
ternally visible tumours, they may also present as internalcen
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ical examination. Hence, the accurate and reliable detec-
tion of all PNF in a given patient with NF1 requires
whole-body magnetic resonance imaging (MRI) [14]. In
this study, we analysed 29 patients with non-mosaic NF1
microdeletions. The number of PNF as well as the total
PNF volume exhibited by these patients has been thor-
oughly analysed by whole-body MRI and volumetric ana-
lysis in a previous study [15]. The 29 patients with NF1
microdeletions analysed here presented with different
numbers of PNF (ranging from 0 to 5 PNF per patient).
The purpose of our study was to examine if there was an
association between ANRIL SNP rs2151280 and theTable 1 Number of plexiform neurofibromas (PNF), tumour vo
with non-mosaic NF1 microdeletions
Patient Age
(years)
Sex Total
tumour
volume (ml)
Rela
tum
volume
682 53 female 0 0
1058 4 female 0 0
748 21 female 0 0
876 15 female 0 0
975 11 male 0 0
991 18 male 0 0
807 18 female 0 0
284 14 female 0 0
1053 28 female 1889 30
272 16 female 258 4
321 23 male 54 0
793 45 male 39 0.4
82 20 female 28 0.3
515 39 female 13 0.1
978 9 female 10 0.3
917 31 female 8 0.1
283 40 female 463 6
726 28 female 215 2.0
941 15 male 20 0.2
463 26 male 5677 77
1056 38 male 4986 59
928 28 female 468 9
714 26 female 321 5.3
579 17 male 8018 11
1057 17 male 3896 62
33 24 male 724 9
857 3 female 656 29
866 16 female 669 10
1059 22 male 247 3.4
a: Tumour volume relative to body weight of the patient on the MRI scan date.
b: The plexiform neurofibromas (PNF) counted were > 3 cm in diameter.
c: as reported in [16], d: as reported in [17], e: published in [18]; f: published in [19]number or volume of PNF observed in patients with NF1
microdeletions.
Methods
Patients and number or volume of PNF
All 29 NF1 patients (or their parents) investigated gave
their written informed consent for the studies to be per-
formed. This study was approved by the university ethics
committees of the participating institutions. The patients
harboured non-mosaic (i.e. constitutional) NF1 microde-
letions (Table 1). The extent of these deletions, as well
as the absence of normal cells without the deletion, has
already been determined by FISH and sequence analysislume and genotype of SNP rs2151280 in 29 patients
tive
our
(ml/kga)
Number
of PNFb
Extent
(type) of NF1
microdeletion
Genotype of
rs2151280
0 1.4-Mb (1)c C/T
0 1.4-Mb (1)c C/T
0 1.4-Mb (1)c C/C
0 1.4-Mb (1)c T/T
0 1.4-Mb (1)c C/C
0 1.4-Mb (1)c C/T
0 1.4-Mb (1)c C/C
0 1.4-Mb (1)c C/T
.5 1 1.4-Mb (1)c C/C
.8 1 3-Mb (atypical)d C/C
.6 1 1.4-Mb (1)c C/C
3 1 1.4-Mb (1)c C/C
5 1 2.7-Mb (atypical)e T/T
5 1 1.4-Mb (1)c C/T
3 1 1.4-Mb (1)c C/T
2 1 1.4-Mb (1)c C/C
.4 2 1.4-Mb (1)c C/T
5 2 1.4-Mb (1)c T/T
8 2 1.4-Mb (1)c C/T
.8 3 2-Mb (atypical)f C/T
.4 3 1.4-Mb (1)c C/T
.0 3 1.3-Mb (atypical)g C/T
5 3 1.4-Mb (1)c C/C
4.5 4 1.4-Mb (1)c C/T
.8 4 1.2-Mb (2)h C/T
.3 4 1.4-Mb (1)c C/C
.8 4 1.4-Mb (1)c C/T
.6 5 1.4-Mb (1)c C/T
3 5 1.4-Mb (1)c C/T
; g: as published in [20]; h: as published in [21].
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blood of the patients as described previously [16-21].
The number of plexiform neurofibromas (PNF) and the
total tumour volume exhibited by the 29 patients with NF1
microdeletions have been investigated in our previous study
by whole-body magnetic resonance imaging (MRI) and
subsequent volumetric evaluation of the tumours [15]. In
brief, the entire body of each patient was investigated in a
series of 10 mm slices performed by the 1.5 Tesla Siemens
Magnetom 63 SP/Symphony/Avanto scanner (Siemens,
Munich, Germany). PNF were detected based on their
characteristic appearance as signal-intense lesions >3 cm in
their longest diameter. The tumour volume was calculated
using MedX software (v3.42; Sensor Systems, Inc, Sterling,
Virginia) as previously described [14]. PNF are often com-
plex tumours that grow along nerves and the extent of each
tumour was carefully evaluated by the analysis of multiple
subsequent images.
Genotype of SNP rs2151280
The genotype of the single nucleotide polymorphism
(SNP) rs2151280, located within intron 3 of the ANRIL
gene, was investigated by PCR amplification of the re-
spective genomic region and subsequent sequence ana-
lysis of PCR fragments amplified from blood-derived
DNA of the 29 patients with NF1 microdeletions. PCRs
were performed with primer 50 GGGAAGAGATGAAG-
TAGTCAATAAAA 30 and primer 50 CCCTCAGCAG-
CACTTATTTTC 30. DNA was extracted from whole
blood using the DNeasy Blood and Tissue Kit (Qiagen,
Hilden, Germany).
Statistical analysis
In order to explore the potential association between the
number of PNF in the 29 patients with NF1 microdele-
tions and the genotype of SNP rs2151280, we used two
different statistical tests, the exact Cochran-Armitage
test for trends and the exact Mann–Whitney–Wilcoxon
test. To assess the extent of any association between the
tumour volume and rs2151280, the exact Mann–Whit-
ney–Wilcoxon test was applied. An adjustment for age
was performed by means of a generalized linear model
with a negative binomial distribution and a log-link
function. Correlations between the number of PNF, the
tumour volume observed and the age of the patients
were tested for by determination of the Spearman rank
correlation coefficient. Statistical analyses were per-
formed using Statistical Analysis System (SAS) software.
Results
In the present study, we investigated the potential associ-
ation between the T-allele of SNP rs2151280 and both the
number and volume of the PNF exhibited by 29 patients
with non-mosaic NF1 microdeletions. These patientsharboured a total of 52 PNF > 3 cm as determined previ-
ously by whole-body magnetic resonance imaging (MRI)
[15]. Tumours smaller than 3 cm in diameter were not
included in the analysis because these tumours cannot be
evaluated by volumetric analysis. At least 13 (25%) of 52
tumours analysed were not visible by external physical
examination but were detected exclusively by MRI.
We used the Cochran-Armitage test for trends to in-
vestigate a potential association between the number of
PNF observed in the 29 patients with NF1 microdele-
tions and SNP rs2151280 . By means of this test, an as-
sociation between variable (a) with two categories and
variable (b) with >2 categories was investigated. In the
context of this study, variable (a) represents the geno-
type of SNP rs2151280 observed in the 29 patients. Vari-
able (a) has been classified into two categories: category
#1 represents the genotypes homozygous for the C-allele
whereas category #2 represents the CT and TT geno-
types of SNP rs2151280. Variable (b) represents the
number of PNF observed, with six distinct categories
being classified, ranging from category #1 (no PNF), cat-
egory #2 (one PNF), category #3 (two PNF) etc. up to
category #6 (five PNF) (Table 1). Within each category
of variable (b), the frequency of categories #1 and #2 of
variable (a) was investigated. In other words, all 29
patients were classified into categories depending upon
the number of PNF observed. Subsequently, the fre-
quency of the CC genotype vs. the CT and TT genotypes
was assessed for each category of patient distinguishable
by PNF number. A significant association between the
PNF number and the frequency of the CC vs. CT/TT
genotypes was not observed (P = 0.20, exact Cochran-
Armitage test for trends).
The number of PNF in the 10 patients with a CC
genotype ranged from 0 to 4 tumours with a mean value
of 1.2 PNF per patient. By contrast, in the 19 patients
with the genotype CT or TT, the number of PNF ranged
from 0 to 5 with a mean value of 2.1. However, the
observed difference between these groups of patients
(those with a CC genotype and those with a CT or TT
genotype) did not attain statistical significance (P = 0.21,
exact Mann-Whitney-Wilcoxon test). Although PNF are
mostly congenital tumours and hence the age of the
patients investigated is not considered to be critical, we
included an adjustment for age in our comparisons.
Again, the difference in the PNF number observed in
both patient groups was not found to be significant (P =
0.16, with an adjustment for age).
We also investigated a putative association between
the tumour volume normalized against body weight and
the rs2151280 genotype (CC vs. CT and TT genotypes)
in the 29 NF1 microdeletion patients. In the group of
patients with the CC genotype, the mean tumour vol-
ume was 5.1 ml/kg whereas the median tumour volume
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with CT or TT genotypes, the mean and median tumour
volume were 19.8 ml/kg and 2.05 ml/kg (95% CI: 0.15 -
29.80), respectively. Although both groups of patients dif-
fered considering the median tumour volume, the confi-
dence intervals overlap to a large extend. A significant
difference in tumour volume was not detected comparing
both groups of patients (P = 0.52, exact Mann–Whitney–
Wilcoxon test; P = 0.19 with adjustment for age). We also
did not observe a significant correlation between the total
tumour volume (not normalized against body weight) or
the number of PNF and the age of patients (ρ = 0.22; P <
0.24; ρ = 0.11; P < 0.58). By contrast, a correlation between
the total tumour volume and the number of tumours was
observed (ρ = 0.87; P < 0.001).
Discussion
The chromosome 9p21.3 region harbours a cluster of
important growth regulatory genes (CDKN2A/ARF and
CDKN2B) that are deleted or transcriptionally silenced
in a wide range of tumours such as plexiform neuro-
fibromas (PNF) [12,22]. The proteins encoded by the
CDKN2A/CDKN2B genes act as inhibitors of the CDK4/
6 cyclin-dependent kinases, thereby regulating the
growth suppressive activity of the RB family of proteins.
By contrast, the ARF protein binds to and inhibits the
oncoprotein MDM2 which activates p53 [11]. The ex-
pression of CDKN2A, ARF and CDKN2B is very low in
both young and non-neoplastic cells but increases dur-
ing cell aging and oncogene-induced hyperproliferation,
suggesting that the coordinated expression of these
genes is a means to regulate senescence and prevent
oncogene-driven hyperproliferation [11]. The polycomb
repressive complexes PRC1 and PRC2 have been shown
to initiate and maintain the silenced state of the
CDKN2A/ARF, CDKN2B gene cluster [23,24]. PRC1 and
PRC2 are recruited to these loci by the 3.8-kb non-
coding RNA ANRIL in order to regulate their expression
[8,10,25,26].
In a family-based association study, Pasmant et al. [7]
investigated a total of five tag SNPs located at 9p21.3 in
1105 individuals (740 NF1 patients and 365 unaffected
individuals from 306 NF1 families) and observed a sig-
nificant association between the number of PNF and one
of these five SNPs, rs2151280. This SNP, located within
intron 3 of the ANRIL gene, was found to be associated
with the number of PNF under a dominant model, with
preferential transmission of the derived T-allele to those
NF1 patients possessing a higher number of PNF. By
contrast, the number of dermal neurofibromas (DNF)
was not found to be associated with rs2151280. Import-
antly, the T-allele of rs2151280 is associated with a
reduced ANRIL expression level suggesting either a
functional role for SNP rs2151280 or that this SNP is inlinkage disequilibrium with an additional as yet un-
known functional variant which influences ANRIL ex-
pression [7]. Taken together, these findings suggested
that modulation of ANRIL expression mediates PNF sus-
ceptibility in patients with NF1. It is unclear how many
patients with NF1 microdeletions were included in the
study of Pasmant et al. [7]. However, only 5% of patients
with NF1 exhibit NF1 microdeletions and familial cases
are very rare.
In this study, we investigated a putative association
between the number or volume of PNF and
rs2151280 in 29 patients with non-mosaic NF1 micro-
deletions. These patients were extremely well charac-
terized by whole-body MRI. We did not observe an
association between the T-allele of rs2151280 and ei-
ther PNF number or PNF volume in these patients,
suggesting that this SNP does not exert a strong ef-
fect on PNF susceptibility in this group of NF1
microdeletion patients. However, we cannot rule out
the possibility of a weak association that might have
remained undetected owing to the small number of
patients investigated. Under the assumption of an
ordered categorical distribution, we estimated that it
would have been necessary to analyze approximately
300 NF1 patients to detect a significant association
between tumour volume and the T-allele with a
power of 80% using the Mann–Whitney–Wilcoxon
test (α=5%). This estimation is however based on the
observations we made in the 29 patients and implies
that the distribution of tumour volumes observed is
representative for the whole population of NF1 micro-
deletion patients. Since NF1 microdeletions are rare
(occurring with an estimated prevalence of 1:70,000),
the whole-body MRI investigation of 300 patients
with NF1 microdeletions is scarcely feasible. As
deduced from the data obtained from the analysis of
the 29 NF1 microdeletion patients, a strong associ-
ation between the T-allele of SNP rs2151280 and the
PNF load is not obvious.
Patients with NF1 microdeletions have been reported
to exhibit a more severe clinical phenotype than patients
with intragenic NF1 mutations, as evidenced by an
increased risk of MPNSTs, severe learning disability,
cognitive impairment, developmental delay and dys-
morphic facial features [16,27-30]. However, the number
of PNF, as determined by whole-body MRI, was not
found to differ significantly between patients with NF1
microdeletions as a group and NF1 patients lacking large
NF1 deletions [15]. Nevertheless, differences in PNF de-
velopment and biology may well exist between both pa-
tient groups i.e. those with NF1 microdeletions and those
with intragenic NF1 mutations. The most common type of
NF1 microdeletion encompasses 1.4-Mb (termed type-1
NF1 deletion) and is associated with the loss of 14 protein-
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the loss of one or several of the genes located within the
NF1 microdeletion region in addition to the deletion of the
NF1 gene, may influence tumour biology or progression. A
good candidate for such a modifier gene influencing
tumour development is SUZ12 which is located within the
1.4-Mb NF1 microdeletion region. One allele of SUZ12 is
deleted in all patients investigated in our study. The SUZ12
protein is an essential component of the polycomb repres-
sive complex 2 (PRC2) and somatic mutations as well as
deletions of SUZ12 have recently been identified in various
haematological malignancies indicating an important role
for chromatin modifiers (such as the polycomb repressive
complexes) in tumorigenesis [34-39]. Remarkably, the poly-
comb repressive complexes 1 and 2 (PRC1 and PRC2) have
also been shown to regulate the expression of the
CDKN2A/ARF and CDKN2B genes. ANRIL directly binds
to SUZ12, an essential component of PRC2 and is required
for SUZ12 occupancy of the CDKN2B locus as well as for
the epigenetic silencing of CDKN2B [8].
The loss of one SUZ12 allele in patients with germline
NF1 microdeletions may well influence ANRIL-mediated
expression regulation of the CDKN2A/CDKN2B tumour
suppressor genes. Although somatic inactivation of the
NF1 wild-type allele is considered to be the PNF-
initiating event in NF1 patients with intragenic muta-
tions and patients with NF1 microdeletions [40], both
patient groups may differ with regard to tumour pro-
gression because of the heterozygous constitutional dele-
tion of SUZ12 present only in patients with NF1
microdeletions. Consistent with this hypothesis, an ex-
tremely high total PNF volume (>3,000 ml) was noted
significantly more frequently in patients with NF1
microdeletions than in NF1 patients without large dele-
tions [15].Conclusions
Our findings in the present study suggest that the puta-
tive modulation of ANRIL expression by the T-allele of
SNP rs2151280 does not influence PNF susceptibility in
patients with NF1 microdeletions. Further studies are
however needed in order to investigate possible differ-
ences in PNF development or susceptibility in NF1
patients with and without NF1 microdeletions.
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